{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:33:11Z","timestamp":1790757191135,"version":"4.1.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"suppl_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,1]]},"DOI":"10.1093\/cid\/cis339","type":"journal-article","created":{"date-parts":[[2012,7,2]],"date-time":"2012-07-02T16:19:01Z","timestamp":1341245941000},"page":"S143-S148","source":"Crossref","is-referenced-by-count":95,"title":["Antimicrobial Activities of Fidaxomicin"],"prefix":"10.1093","volume":"55","author":[{"given":"Ellie J. C.","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Babakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane M.","family":"Citron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,8,1]]},"reference":[{"key":"key\n\t\t\t\t20171014000105_CIS339C1","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.35.6.1108","article-title":"In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile","volume":"35","author":"Swanson","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000105_CIS339C2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7164\/antibiotics.40.567","article-title":"Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity","volume":"40","author":"Theriault","year":"1987","journal-title":"J Antibiot"},{"key":"key\n\t\t\t\t20171014000105_CIS339C3","article-title":"Antimicrobial activity and post-antibiotic effect of OPT-89, a new macrocyclic compound, against Clostridium difficile [abstract]","author":"Babakhani"},{"key":"key\n\t\t\t\t20171014000105_CIS339C4","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1128\/AAC.48.6.2280-2282.2004","article-title":"In vitro activity of OPT-80 against Clostridium difficile","volume":"48","author":"Ackermann","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000105_CIS339C5","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/AAC.48.12.4898-4902.2004","article-title":"In vitro activities of OPT-80 and comparator drugs against anaerobic bacteria","volume":"48","author":"Finegold","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000105_CIS339C6","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000105_CIS339C7","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1128\/AAC.48.11.4430-4434.2004","article-title":"Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species","volume":"48","author":"Credito","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000105_CIS339C8","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1128\/AAC.00476-08","article-title":"In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile","volume":"52","author":"Karlowsky","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000105_CIS339C9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.anaerobe.2009.09.005","article-title":"Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection","volume":"15","author":"Citron","year":"2009","journal-title":"Anaerobe"},{"key":"key\n\t\t\t\t20171014000105_CIS339C10","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1128\/AAC.00625-11","article-title":"Comparative susceptibilities of fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two fidaxomicin phase III trials of C. difficile infection","volume":"55","author":"Goldstein","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000105_CIS339C11","volume-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria","author":"Clinical and Laboratory Standards Institute","year":"2007","edition":"7th ed"},{"key":"key\n\t\t\t\t20171014000105_CIS339C12","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1128\/AAC.01842-09","article-title":"Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile","volume":"54","author":"Babakhani","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000105_CIS339C13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.01443-07","article-title":"OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000105_CIS339C14","article-title":"Narrow spectrum activity and low fecal binding of OPT-80 and its major hydrolysis metabolite (OP-1118) [abstract E-2076]","author":"Babakhani"},{"key":"key\n\t\t\t\t20171014000105_CIS339C15","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1099\/jmm.0.029470-0","article-title":"Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile","volume":"60","author":"Babakhani","year":"2011","journal-title":"J Med Microbiol"},{"key":"key\n\t\t\t\t20171014000105_CIS339C16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/AAC.01442-07","article-title":"Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000105_CIS339C17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijantimicag.2009.07.003","article-title":"Frequency and characterization of spontaneous lipiarmycin-resistant Enterococcus faecalis mutants selected in vitro","volume":"34","author":"Gultieri","year":"2009","journal-title":"Int J Antimicrobial Agents"},{"key":"key\n\t\t\t\t20171014000105_CIS339C18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jac\/dkn269","article-title":"Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis","volume":"62","author":"Kurabachew","year":"2008","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/55\/suppl_2\/S143\/20910983\/cis339.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T00:01:16Z","timestamp":1507939276000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/55\/suppl_2\/S143\/435404\/Antimicrobial-Activities-of-Fidaxomicin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":18,"journal-issue":{"issue":"suppl_2","published-online":{"date-parts":[[2012,8,1]]},"published-print":{"date-parts":[[2012,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cis339","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2012,8,1]]},"published":{"date-parts":[[2012,8,1]]}}}